TUFT1 is expressed in breast cancer and involved in cancer cell proliferation and survival
Metrics: PDF 1305 views | HTML 2402 views | ?
Weiguang Liu1, Lei Zhang1, Zining Jin1, Min Zhao1, Zhan Li1, Guanglei Chen2, Lisha Sun1 and Bo Chen1
1Department of Breast Surgery, The First Hospital of China Medical University, Shenyang 110001, Liaoning Province, China
2Department of Breast Surgery, The Second Hospital of Dalian Medical University, Dalian 116000, Liaoning Province, China
Bo Chen, email: [email protected]
Keywords: TUFT1, breast cancer, proliferation, apoptosis, prognosis
Received: March 29, 2017 Accepted: July 19, 2017 Published: August 24, 2017
Tuftelin 1 (TUFT1), which plays an important role in the initial stages of the mineralization of ectodermal enamel, is widely expressed in different embryonic and adult tissues and some tumor cells. However, since the roles of this gene have not been thoroughly investigated in tumors, its function in the development of breast cancer remains unclear. We proved both human specimens studies and cell line studies, that TUFT1 expression levels are increased in breast cancer samples, and the increased expression of TUFT1 was shown to be positively correlated with tumor size, histological grade, lymph node metastasis rate, and poor prognosis. Further in vitro studies showed that the inhibition of TUFT1 expression in T-47D and MDA-MB-231 breast cancer cells significantly affected cell proliferation, induced apoptosis, and led to G1-phase cell cycle arrest. Moreover, reduced TUFT1 expression restrained tumor growth compared with the control group in vivo. Furthermore, microarray and pathway analysis demonstrated that TUFT1 inhibition led to significant changes of several signaling pathways and semi-quantitative western blot analysis showed that a decrease in TUFT1 expression was accompanied by changes in MAPK signaling pathway components. The obtained results suggest that TUFT1 may represent a novel breast cancer marker and a potentially effective therapeutic target.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.